What can we currently learn from new prognostic markers of chronic lymphocytic leukemia in the everyday haematological practice?;Co nám v každodenní praxi skutečně říkají tzv. moderní prognostické faktory u chronické lymfatické leukemie?

Transfuze a Hematologie Dnes

Volumn 13, Issue 3, 2007, Pages 106-116

  Mayer, Jiří ^a   Schwarz, J ^b   Doubek, M ^a   Brychtova Y ^a   Brejcha, M ^c   Pospisilova S ^a   Trbusek M ^a   Kuhrova V ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^c Onkologicke Centrum J G Mendela   (Czech Republic)

Author keywords

Chronic lymphocytic leukemia; New prognostic factors; Treatment

Indexed keywords

ATM PROTEIN; CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; MICRORNA; PROTEIN KINASE ZAP 70; PROTEIN P53;

CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CLINICAL RESEARCH; CYTOGENETICS; GENE MUTATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; PATHOGENESIS; PATIENT CARE; PROGNOSIS; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION;

EID: 36448939795     PISSN: 12135763     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Gine E, Bosch F, Rozman M, et al. Fludarabine therapy abrogates the prognostic significance of bone marrow histological pattern in chronic lymphocytic leukemia. Blood 2003; 102: 673a, abstract No 2492.
2. Papajík T, Jarošová M, Pikalová Z, Indrák K. Chronická B-lymfocytární leukemie. Část II: Diagnostická kritéria a význam stanovení individuální prognózy nemocného. Trans Hemat dnes 2006; 12: 132-139.
3. Cmunt E, Trněný M, Karban J, Šálková J, Michalová K, et al. Analýza rizikových faktorů u 248 pacientů s chronickou B-lymfocytární leukemií vyšetřených v době diagnózy. Trans Hemat dnes 2006; 12: 232-239.
4. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
5. Binet JL, Lepoprier M, Dighiero G, Charron D, D'Athis P, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977; 40: 855-864.
6. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
7. Montserrat E, Rozman C. Chronic lymphocytic leukaemia: prognostic factors and natural history. Baill Clin Haematol 1993; 6: 849-866.
8. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 1998; 25: 42-59.
9. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
10. Jarošová M, Jedličková K, Holzerová M, Urbanová R, Papajík T, et al. Přínos metod molekulární cytogenetiky pro určení prognosticky významných chromozomových změn u nemocných s chronickou lymfatickou leukémií. Čas Lék čes 2000; 139: 564-569.
11. Michalová K, Zemanová Z, Cmunt E, Karban J, Březinová J, et al. Význam interfázické fluorescenční in situ hybridizace (I-FISH) pro vyšetření nemocných s chronickou lymfatickou leukemií (CLL). Čas Lék čes 2000; 139: 334-338.
12. Robak T, Dmoszynska A, Fetni R, Wang Y, Belkacz M, et al. Incidence of genomic aberrations and associated efficacy from a phase III study comparing alemtuzumab (Campath, Mabcampath) vs chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia. Blood 2006; 108: 593a, abstract No 2092.
13. Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 4634-4641.
14. Stilgenbauer S, Krober A, Busch R, et al. 17p deletion predicts for inferior overall survival after fludarabine - based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG. Blood 2006; 106: 212a, abstract No 715.
15. Hillmen P, Skotnicki A, Robak T, Jaksic B, Sirard C, Mayer J. Alemtuzumab (Campath, Mabcampath) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia. Blood 2006; 108: 93a, abstract No 301.
16. H status, and CD38 expression. Blood 2006; 108: 3152-3160.
17. Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006; 107: 724-751.
18. Dreyer WJ, Bennet JC. The molecular basis of antibody formation: a paradox. Proc Nat Acad Sci USA 1965; 54: 864-869.
19. Schroeder HW, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994; 15: 288-294.
20. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102: 1515-1525.
21. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
22. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
23. Kuhrová V, Francová H, Klimešová D, Brychtová Y, Doubek M, et al. Molekulárně-genetická charakterizace agresitivy chronické lymfocytární leukémie u českých pacientů: nukleotidová variabilita genů kódujících syntézu těžkého řetězce imunoglobulinů. Čas Lék čes 2006; 145: 855-858.
24. Lane BS, Mensah AA, Lin K, Pettitt AR, Sherrington PD. Analysis of VH gene sequences using two web-based immunogenetics resources gives different results, but the affinity maturation status of chronic lymphocytic leukaemia clones as assessed from either of the resulting data sets has no prognostic significance. Leukemia 2005; 19: 741-749.
25. Davis ZA, Orchard JA, Corcoran MM, Oscier DG. Divergence from the germ-line sequence in unmutated chronic lymphocytic leukemia is due to somatic mutation rather than polymorphism. Blood 2003; 102: 3075.
26. H genes? Blood 2004; 104: 219a, abstract No 767.
27. H3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99: 2262-2264.
28. Vasconcelos Y, Davi F, Levy V, Oppezzo P, Magnac C, et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol 2003; 21: 3928-3932.
29. Moreno C, Villamor N, Colomer D, Esteve J, Gine E, et al. Allogeneic stem cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3433-3438.
30. Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006; 108: 1135-1144.
31. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023-1029.
32. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181-186.
33. Thornton PD, Fernandez C, Giustolisi GM, Morilla R, Atkinson S, et al. CD38 expression as a prognostic indicator in chronic lymphocytic leukemia. Hematol J 2004; 5: 145-151.
34. Ghia P, Guida G, Stella S, Gottardi B, Geuna M, et al. The pattern of CD38 expression defines a distict subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101: 1262-1296.
35. Calissano C, Damle R, Benapour T, et al. In vivo labeling of newly synthesized DNA suggest that the CD38+ fraction in enriched in proliferating cells within a clone of chronic lymphocytic leukemia B cells. Blood 2006; 108: 12a, abstract No 27.
36. Pospíšilová Š, Mayer J. DNA čipy - moderní metodika analýzy diferenciální genové exprese a její význam pro diagnostiku a léčbu nádorových onemocnění. Čas Lék čes 2005; 144: 11-17.
37. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639-1647.
38. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1765.
39. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101; 2003: 4944-4951.
40. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Eng J Med 2004; 351: 839-901.
41. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105-111.
42. Scielzo C, Camporeale A, Geuna M, Alessio M, Poggi A, et al. ZAP-70 is expressed by normal and malignant human B-cells subsets of different maturation stage. Leukemia 2006; 20: 689-695.
43. Trbušek M, Malčíková J, Šmardová J, Kuhrová V, Mentzlová D, et al. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia 2006; 20: 1159-1161.
44. Carter A, Lin K, Sherrington PD, Atherton M, Pearson K, et al. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukemia. Leukemia 2006; 20: 737-740.
45. Lucas DM, Dewald GW, Neuberg DS, et al. Clinical, laboratory, and treatment outcome characteristics of chronic lymphocytic leukemia patients with p53 mutations or del/17p) enrolled on prospective phase III clinical trial: short progression free survival, irrespective of fludarabine-based treatment used. Blood 2004; 104: 272a, abstract No 949.
46. Austen B, Powel JE, Alvi A, Edwards I, Hooper L, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of VGVH mutation status in patients with B-CLL. Blood 2005; 106: 3175-3182.
47. Štruncová S, Borská R, Kusenda B, Mejstřík P, Dvořáková D, Mayer J, Pospíšilová Š. RNA interference - účinný nástroj regulace genové exprese. Biol Listy 2005; 70: 231-247.
48. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801.
49. Kröber A, Bloehdorn J, Hafner S, Buhler A, Seiler T, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 969-975.
50. Del Giudice I, Ghia EM, De Propris SM, et al. Chronic lymphocytic leukemia with discordance in ZAP-70 expression and IgVH mutation status. Blood 2006; 108: 789a, abstract No 2787.
51. Guarini A, Gaidano G, Mauro FR, Capello D, Mancini F, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood 2003; 102: 1035-1041.
52. Gardiner A, Davis Z, Anton P, et al. Defining the 10 year risk of the disease progression in stage A0 CLL. Blood 2006; 108: 785a, abstract No 2772.
53. Grever MR, Dewald GW, Neuberg DS, et al. Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphovcytic leukemia: prospective randomized trial (Intergroup E2997) to evaluate justification for risk-adapted therapy. J Clin Oncol 2006; 24: 342a, abstract No 6521.
54. Catovsky D, Richards S, Matutes E, et al. Response to therapy and survival in CLL is influenced by genetic markers. Preliminary analysis from the LRF CLL4 trial. Blood 2004; 104: 8a, abstract No 13.
55. Oscier DG, Wade R, Orchard J, et al. Prognostic factors in the UK LRF CLL4 trial. Blood 2006; 108: 92a, abstract No 299.
56. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437-443.
57. H mutation status in patients with B-cell chronic lymphocytic leukemia. Haematologica 2006; 91: 1432-1433.
58. Binet JL, Caligaris-Capio F, Catovsky D, Cheson B, Davis T, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006; 107: 859-861.
59. Zent CS, Call TG, Hogan WJ, Shanafelt TD, Kay NE. Update on risk - stratified management for chronic lymphocytic leukemia. Leukemia Lymphoma 2006; 47: 1738-176.